Clinical study
Aptahem's CEO sees continued interest in Apta-1
Aptahem is moving forward with its first clinical study with the sepsis candidate Apta-1. In parallel, the company has ramped up its activities to...
Intervju
CEO interview 2cureX: »The data supports our belief in the IndiTreat technology«
Yesterday, 2cureX reported positive interim data for IndiTreat, a...
Saniona reaches its most important milestone to date
One of the largest players in South America in obesity...
Interview: FDA announcement gives backing to BrainCool's migraine initiative
When BrainCool acquired competitor Benechill last year, the company strengthened its already...